Skip to content

AARD AARD Free cash flow

Free cash flow at other companies

AbbVie logo
AbbVieABBV
$3.56B+155%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
-$14.86M+36.9%
Arvinas logo
ArvinasARVN
-$70.5M+21.1%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-$49.16M-139%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$138M-3.8%

Other financials

Income statement

See full
Revenue-
Operating income-$22.5M-115%
Net income-$21.6M-132%
EPS (diluted)-$0.99-39.4%

Balance sheet

See full
Cash & equivalents$62.4M+136%
Total debt$336.0K-53.7%
Total equity$87.0M-42.3%
Total assets$98.6M-37.2%

Cash flow

See full
Operating cash flow-$18.9M-65.7%
CapEx--100%

Valuation

See full
Market cap$124.35M-58.6%
Enterprise value$62.25M-77.4%

Returns & leverage

See full
Return on equity-58.8%
Debt / equity0.0×
Current ratio8.1×-17.8×

Where this comes from

Calculated from AARD’s reported figures.

The official record: AARD’s 10-K, filed March 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about AARD's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AARD's free cash flow?
AARD (AARD) reported free cash flow of -$16.81M in Q4 2025.
How has AARD's free cash flow changed year-over-year?
AARD's free cash flow decreased by 117.4% year-over-year, from -$7.73M to -$16.81M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.